Could a vaccine stop cancer before it starts? new trial for lynch syndrome
NCT ID NCT05078866
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a vaccine called Nous-209 in 45 people with Lynch syndrome, an inherited condition that raises the risk of colorectal and other cancers. The vaccine is designed to train the immune system to recognize and attack cells with cancer-like changes. Researchers want to see if the vaccine is safe and whether it triggers an immune response that could prevent polyps or tumors from forming.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
Conditions
Explore the condition pages connected to this study.